BayBio Notes
<< < 80 90 98 99 100 101 102 110 120 200 > >>
- Biotech IPOs look strong — with haircuts - Jul 5, 2011
One of the many takeaways from BIO2011 was data from Elsevier Business Intelligence showing that biotech IPOs actually are doing quite well — up 42 percent post-IPO. Of course, that’s after...
Read More... - Entrepreneurial Walk of Fame Looking Real—September 16 Launch Targeted - Jul 5, 2011
Read More... - Optivia Biotech Finds its Way to Profits, With a Little Help from Friends at the FDA - Jul 5, 2011
Read More... - Life Science Events and Jobs Await Your Return from Holidays! - Jul 2, 2011
Hi, Thought I’d get both upcoming meeting list and latest jobs that crossed my desk to you prior to your July 4th barbecue preparation. There’s only one event for this coming week in which you...
Read More... - XenoPort Announces New Employment Inducement Award - Jul 1, 2011
SANTA CLARA, Calif.--(BUSINESS WIRE)--XenoPort, Inc. (Nasdaq:XNPT) reported today that an equity award was made to a new employee subject to the terms and conditions of the XenoPort 2010 Inducement...
Read More... - Northeast Scientific, Inc. and EXP Pharmaceutical Services Corp. Offer Surgical Package Renewal for the Repackaging and Resterilization of Open-But-Unused, Breached or Date-Expired Medical Device Packaging - Jun 30, 2011
WATERBURY, Conn. & FREMONT, Calif.--(BUSINESS WIRE)--EXP Pharmaceutical Services announces partnership for Surgical Package Renewal, the repackaging and resterilization of Open-But-Unused,...
Read More... - Impax Laboratories Announces Settlement of Litigation Relating to WELCHOL® Tablets and WELCHOL® Oral Suspension Products - Jun 30, 2011
HAYWARD, Calif.--(BUSINESS WIRE)--Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it has reached agreement with Daiichi Sankyo, Inc. and Genzyme Corporation to settle pending patent...
Read More... - Sorbent Therapeutics Absorbs $36M to Go After New Treatment For Kidney, Heart Failure - Jun 30, 2011
Read More... - AEGEA Medical Reports Completion of $13.3 Million Financing - Jun 30, 2011
REDWOOD CITY, Calif.--(BUSINESS WIRE)--AEGEA Medical, developer of novel, minimally invasive treatment for abnormal uterine bleeding has completed a successful financing.
Read More... - Genentech finds companions on road to drug development - Jun 30, 2011
<span class='rssImage'><img...
Read More... - This Drug Didn’t Work for Me. May I Have My $88,000 Back, Please? - Jun 30, 2011
Read More... - Genentech finds diagnostic companions on road to drug development - Jun 30, 2011
Perhaps Genentech has a new slogan in the works: Have companion diagnostic, will travel.<br />The South San Francisco-based U.S. subsidiary of Swiss drug maker Rochefor the past couple years...
Read More... - Bay Area transplant Sorbent Therapeutics raises $53M - Jun 30, 2011
Sorbent Therapeutics Inc. closed a $53 million Series B financing round led by new investor Novartis Venture Funds. A Bay Area transplant from Chicago, the three-employee Sunnyvale company will...
Read More... - Bay Area transplant Sorbent Therapeutics closes $53M Series B financing - Jun 30, 2011
Sorbent Therapeutics Inc. closed a $53 million Series B financing round led by new investor Novartis Venture Funds.<br />A Bay Area transplant from Chicago, the three-employee Sunnyvale...
Read More... - AHF Challenges Gilead over AIDS Drug Pricing During Protest at Foster City HQ - Jun 29, 2011
SAN FRANCISCO--(BUSINESS WIRE)--AHF challenges Gilead over AIDS drug pricing during protest at Foster City HQ--In 2010, Gilead had $6.5 billion in AIDS drug sales, enjoying a 36.5% profit margin
Read More... - Genentech Shot Down at FDA Hearing on Avastin for Breast Cancer - Jun 29, 2011
Read More... - Reaction to FDA's Avastin decision - Jun 29, 2011
Here's some of the reaction from Wednesday's Food and Drug Administration advisory panel recommendation to remove approval of Avastin, developed by South San Francisco's Genentech,...
Read More... - FDA panel rejects Genentech's Avastin for breast cancer - Jun 29, 2011
<span class='rssImage'><img src='http://assets.bizjournals.com/http://assets.bizjournals.com/sanfrancisco/Avastin%20NEW%20SQ*100.jpg?v=1'></span>A regulatory...
Read More... - Reaction to FDA's Avastin decision - Jun 29, 2011
Here's some of the reaction from Wednesday's Food and Drug Administration advisory panel recommendation to remove approval of Avastin, developed by South San Francisco's Genentech ,...
Read More... - FDA panel votes against Genentech's Avastin - Jun 29, 2011
A regulatory panel recommended that Genentech Inc. ’s cancer-fighting drug Avastin not win full approval for treating women for breast cancer that has spread to other parts of the body.<br...
Read More...
